Zenflow is a South San Francisco, CA-based medical device company developing minimally invasive therapies for benign prostatic hyperplasia (BPH). Its flagship Zenflow Spring System is an in-office prostatic urethral implant that delivers durable symptom relief with multiple sizing options, preserved sexual function and full reversibility, with 99% of patients catheter-free after the procedure. The Spring System received FDA PMA approval in December 2025, completed its first commercial procedures at four U.S. centers in September 2026, and is distributed in the U.S. through an exclusive partnership with Cook Medical.
1
Round
1
Industry
4
Tags
Oct 5, 2026
Latest raise
Funding activity · 1 round
Oct 5, 2026
$52M
Series C+
Led by Cook Medical
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
